Additionally, the prognostic and predictive role of molecular abnormalities has clearly emerged (e.g., relatively good chemosensitivity of NPM1-mutated AML, dismal results in TP53-mutated ones, recently reviewed in [172]), but their interaction with cytogenetics is complex, and should also be carefully considered. This evidence concerns the gene TP53 and acute myeloid leukemia.